Detalhe da pesquisa
1.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
; 142(14): 1208-1218, 2023 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366170
2.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
3.
How I treat AL amyloidosis.
Blood
; 139(19): 2918-2930, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34517412
4.
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival.
Blood
; 140(18): 1964-1971, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772003
5.
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
Hematol Oncol
; 42(4): e3289, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38824453
6.
Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy.
Neurol Sci
; 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622453
7.
Individualized Approach to Management of Light Chain Amyloidosis.
J Natl Compr Canc Netw
; 21(1): 91-98, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36634608
8.
Advances in the treatment of light chain amyloidosis.
Curr Opin Oncol
; 34(6): 748-756, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35943427
9.
Management of AL amyloidosis in 2020.
Blood
; 136(23): 2620-2627, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33270858
10.
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Blood
; 135(18): 1531-1540, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32108228
11.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood
; 136(1): 71-80, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244252
12.
Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies.
J Magn Reson Imaging
; 56(4): 1157-1170, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35075711
13.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
14.
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients.
Clin Chem Lab Med
; 60(3): 386-393, 2022 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35018751
15.
Cu(II) Binding Increases the Soluble Toxicity of Amyloidogenic Light Chains.
Int J Mol Sci
; 23(2)2022 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35055136
16.
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
J Biol Chem
; 295(49): 16572-16584, 2020 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32952127
17.
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis.
Eur J Clin Invest
; 51(11): e13598, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33982288
18.
Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Medicina (Kaunas)
; 57(9)2021 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-34577839
19.
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.
Br J Haematol
; 190(3): 346-357, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32480420
20.
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Blood
; 131(5): 525-532, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29101236